All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @myriamestrella8 on TikTok · 11s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @myriamestrella8's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00It's all!

@myriamestrella8's weight loss claims, fact-checked

myriam gets healthy 😁

TikTok creator

15.4K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide and tirzepatide work by slowing gastric emptying and reducing appetite through brain receptors. Clinical trials show 14.9% to 22.5% average body weight loss over 68-72 weeks when combined with lifestyle interventions.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @myriamestrella8's weight loss claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@myriamestrella8's weight loss claims, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@myriamestrella8's weight loss claims, fact-checked" from myriam gets healthy 😁. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide work by slowing gastric emptying and reducing appetite through brain receptors.

The reason this review is not generic is the source wording and the canonical claim label "glp1 i m down 1 1 5 lbz i get my meds from mochi linked in bio." In this clip, the useful excerpt is: "It's all!" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Tirzepatide showed 22.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide and tirzepatide work by slowing gastric emptying and reducing appetite through brain receptors.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and tirzepatide work by slowing gastric emptying and reducing appetite through brain receptors. Clinical trials show 14.9% to 22.5% average body weight loss over 68-72 weeks when combined with lifestyle interventions.
  • Semaglutide produced 14.9% average weight loss in the STEP 1 trial over 68 weeks
  • Tirzepatide showed 22.5% average weight loss in SURMOUNT-1 over 72 weeks

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Semaglutide produced 14.9% average weight loss in the STEP 1 trial over 68 weeks
  • Tirzepatide showed 22.5% average weight loss in SURMOUNT-1 over 72 weeks
  • Clinical trials combined medications with 500-calorie daily reductions and lifestyle counseling
  • About 32% of participants lost at least 20% of body weight, but results vary widely
  • Participants regained two-thirds of lost weight within one year after stopping medication
  • Mochi Health prescribes legitimate FDA-approved GLP-1 medications through licensed providers
  • The affiliate marketing structure creates financial incentives that may influence testimonials

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this video actually claim?

@myriamestrella8 says she's lost 115 pounds using medication from Mochi Health, a telehealth platform that prescribes GLP-1 receptor agonists. She's promoting the service with a discount code and affiliate links.

The video doesn't specify which medication she's using or over what timeframe. She attributes her entire weight loss to the medication without mentioning diet, exercise, or other factors that typically accompany successful weight management programs.

Is 115 pounds of weight loss realistic with GLP-1 drugs?

Yes, but it depends heavily on starting weight and timeframe. The STEP 1 trial (Wilding et al., NEJM, 2021) showed 14.9% average body weight loss with 2.4mg semaglutide over 68 weeks.

For someone starting at 350 pounds, 14.9% would equal about 52 pounds. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) found 22.5% average weight loss with 15mg tirzepatide over 72 weeks. That same 350-pound person might lose around 79 pounds.

Losing 115 pounds is possible with these medications, but it would require either a very high starting weight or being in the top percentile of responders. The creator doesn't provide enough context to evaluate her specific results.

What's missing from this success story?

The timeframe matters enormously. Losing 115 pounds over two years is very different from losing it over six months, but we can't tell from the video.

Most clinical trials of GLP-1 medications include lifestyle counseling, structured meal plans, and exercise programs. The STEP 1 participants received monthly counseling sessions and were instructed to reduce caloric intake by 500 calories daily.

Attributing all weight loss solely to medication oversimplifies what's typically a comprehensive approach. Even the most effective GLP-1 drugs work best when combined with dietary changes.

Is Mochi Health a legitimate option?

Mochi Health is a real telehealth platform that prescribes FDA-approved GLP-1 medications through licensed providers. They offer semaglutide and tirzepatide, the same active ingredients in brand-name drugs like Ozempic and Mounjaro.

However, the affiliate marketing setup here raises questions about motivation. When someone earns money from referrals, their testimonial becomes advertising rather than pure personal experience.

The discount code structure suggests this is part of an influencer partnership program. That doesn't invalidate her results, but it does mean viewers should consider the financial incentive behind the recommendation.

What should you actually know about GLP-1 weight loss?

These medications can produce substantial weight loss, but individual results vary widely. In the STEP trials, about 32% of participants lost at least 20% of their body weight, while others saw minimal results.

Starting doses are typically much lower than maintenance doses. Semaglutide begins at 0.25mg and increases gradually to 2.4mg over 16-20 weeks to minimize side effects like nausea and vomiting.

The medications require ongoing use to maintain weight loss. When participants stopped semaglutide in follow-up studies, they regained about two-thirds of their lost weight within one year. This makes them a long-term commitment rather than a short-term solution.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

myriam gets healthy 😁 · TikTok creator

15.4K views on this video

I’m down 1-1-5 lbz!! I get my meds from Mochi (linked in bio - used code LFFAVV to save $$) 💙🙏 @Mochi Health #joinmochi #mochihealth #mochipartner

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about semaglutide produced 14.9% average weight loss in the step 1?

Semaglutide produced 14.9% average weight loss in the STEP 1 trial over 68 weeks

What does the video say about tirzepatide showed 22.5% average weight loss in surmount-1 over 72?

Tirzepatide showed 22.5% average weight loss in SURMOUNT-1 over 72 weeks

What does the video say about clinical trials combined medications with 500-calorie daily reductions?

Clinical trials combined medications with 500-calorie daily reductions and lifestyle counseling

What does the video say about about 32% of participants lost at least 20% of body?

About 32% of participants lost at least 20% of body weight, but results vary widely

What does the video say about participants regained two-thirds of lost weight within one year after?

Participants regained two-thirds of lost weight within one year after stopping medication

What does the video say about mochi health prescribes legitimate fda-approved glp-1 medications through licensed providers?

Mochi Health prescribes legitimate FDA-approved GLP-1 medications through licensed providers

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by myriam gets healthy 😁, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.